BLING III

Beta-lactam antibiotics infusion group study

PICO Question

  • Population: ICU patients receiving Tazocin or meropenem for sepsis

  • Interventions: Continuous infusions of beta-lactam antibiotics

  • Comparison: Usual care

  • Outcomes: 90-day mortality, unit-acquired infections

Recruitment

Inclusion criteria

Exclusion criteria

  • Documented/strong suspicion of infection

  • Expected to be in ICU >24h

  • Started Tazocin or meropenem

  • ≥1 organ dysfunction in previous 24h

  • Aged < 18 years

  • Recieved Tazocin or meropenem for >24h during current infection

  • Pregnant

  • Tazocin/meropenem allergy

  • Need for RRT

  • Planned withdrawal within 48h

  • Previously enrolled in this trial.

Details

PreviousADAPT-SepsisNextEFFORT

Last updated

Was this helpful?